Medesis Pharma S.A. (ALMDP.PA)
EUR 0.35
(0.0%)
EUR 0.35
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.66 Million EUR | -20.85% |
| 2022 | -2.2 Million EUR | -1.6% |
| 2021 | -2.17 Million EUR | -336.53% |
| 2020 | -497.18 Thousand EUR | -255.14% |
| 2019 | -140 Thousand EUR | 60.34% |
| 2018 | -353 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | -861.54 Thousand EUR | 0.0% |
| 2023 Q2 | -470.84 Thousand EUR | 0.0% |
| 2023 Q1 | -470.84 Thousand EUR | -12.99% |
| 2023 Q3 | -861.54 Thousand EUR | -82.98% |
| 2023 FY | -2.66 Million EUR | -20.85% |
| 2022 Q1 | -610.84 Thousand EUR | 4.96% |
| 2022 Q4 | -416.7 Thousand EUR | 0.0% |
| 2022 Q3 | -416.7 Thousand EUR | 31.78% |
| 2022 Q2 | -610.84 Thousand EUR | 0.0% |
| 2022 FY | -2.2 Million EUR | -1.6% |
| 2021 FY | -2.17 Million EUR | -336.53% |
| 2021 Q4 | -642.73 Thousand EUR | 0.0% |
| 2021 Q3 | -642.74 Thousand EUR | -45.27% |
| 2021 Q2 | -442.45 Thousand EUR | 0.0% |
| 2021 Q1 | -442.45 Thousand EUR | -275.25% |
| 2020 FY | -497.18 Thousand EUR | -255.14% |
| 2020 Q4 | -117.9 Thousand EUR | 0.0% |
| 2020 Q3 | -117.9 Thousand EUR | 9.78% |
| 2020 Q1 | -130.68 Thousand EUR | 0.0% |
| 2020 Q2 | -130.68 Thousand EUR | -0.0% |
| 2019 FY | -140 Thousand EUR | 60.34% |
| 2018 FY | -353 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 531.192% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 168.083% |
| Adocia SA | 1.38 Million EUR | 292.402% |
| Aelis Farma SA | 12.35 Million EUR | 121.563% |
| Biophytis S.A. | -803 Thousand EUR | -231.852% |
| Advicenne S.A. | 1.42 Million EUR | 286.87% |
| genOway Société anonyme | 20.1 Million EUR | 113.257% |
| IntegraGen SA | 5.01 Million EUR | 153.101% |
| Neovacs S.A. | 29.31 Thousand EUR | 9190.428% |
| NFL Biosciences SA | -56.06 Thousand EUR | -4653.082% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 223.775% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | -87.754% |
| Sensorion SA | 3.78 Million EUR | 170.35% |
| Theranexus Société Anonyme | -4.63 Million EUR | 42.553% |
| TME Pharma N.V. | -127 Thousand EUR | -1998.243% |
| Valbiotis SA | 2.66 Million EUR | 199.879% |
| TheraVet SA | -530.79 Thousand EUR | -402.032% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 310.321% |
| DBV Technologies S.A. | 4.15 Million EUR | 164.063% |
| Genfit S.A. | 28.22 Million EUR | 109.441% |
| GeNeuro SA | -293.8 Thousand EUR | -807.001% |
| Innate Pharma S.A. | -4.12 Million EUR | 35.337% |
| Inventiva S.A. | 17.5 Million EUR | 115.227% |
| MaaT Pharma SA | 1.65 Million EUR | 261.013% |
| MedinCell S.A. | 9.28 Million EUR | 128.69% |
| Nanobiotix S.A. | 36.2 Million EUR | 107.36% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 219.657% |
| Poxel S.A. | 1000.00 EUR | 266576.8% |
| GenSight Biologics S.A. | 3 Million EUR | 188.826% |
| Transgene SA | -28.4 Million EUR | 90.618% |
| Valneva SE | 52.83 Million EUR | 105.043% |